Publicacións nas que colabora con Irene Zarra Ferro (18)

2025

  1. Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations

    Scientific Reports, Vol. 15, Núm. 1

2024

  1. Clinical Effectiveness, Safety, and Compliance of Two Compounded Formulations of Tacrolimus Eye Drops: An Open-Label, Sequential Prospective Study

    International Journal of Molecular Sciences, Vol. 25, Núm. 18

  2. Role of CYP2D6 and CYP3A4 polymorphisms on aripiprazole and dehydroaripiprazole concentrations in patients undergoing long-acting treatment

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 135

  3. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  2. Correction: A Review of Population Pharmacokinetic Analyses of Linezolid (Clinical Pharmacokinetics, (2022), 61, 6, (789-817), 10.1007/s40262-022-01125-2)

    Clinical Pharmacokinetics

  3. Design and biopharmaceutical preclinical characterisation of a new thermosensitive hydrogel for the removal of gastric polyps

    International Journal of Pharmaceutics, Vol. 635, pp. 122706

2022

  1. A Review of Population Pharmacokinetic Analyses of Linezolid

    Clinical Pharmacokinetics, Vol. 61, Núm. 6, pp. 789-817

  2. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence

    Pharmaceutics, Vol. 14, Núm. 10

2021

  1. Development and characterization of inhaled ethanol as a novel pharmacological strategy currently evaluated in a phase ii clinical trial for early-stage sars-cov-2 infection

    Pharmaceutics, Vol. 13, Núm. 3

  2. Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy

    Cancer Chemotherapy and Pharmacology, Vol. 88, Núm. 5, pp. 813-823

  3. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7

  4. Therapeutic drug monitoring of voriconazole: Validation of a high performance liquid chromatography method and comparison with an ARK immunoassay

    European Journal of Hospital Pharmacy, Vol. 28, Núm. 3, pp. 154-159

2020

  1. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 8, pp. 1661-1666

  2. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study

    Pharmacotherapy, Vol. 40, Núm. 1, pp. 17-25

  3. Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration

    International Journal of Pharmaceutics, Vol. 573

  4. PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 154, pp. 330-337

2019

  1. Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration

    Pharmaceutics, Vol. 11, Núm. 8